SCHEMBL13798596

SCHEMBL13798596

CCN[C@@H](C)COC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18331589 1.00
SCHEMBL12072033 1.00
SCHEMBL29320555 0.84 HSD17B10 (0.32)
SCHEMBL7878259 0.79
SCHEMBL6980345 0.79
SCHEMBL13520204 0.79
SCHEMBL19983135 0.79 SIGMAR1 (0.31)
SCHEMBL24819144 0.76 ALDH1A1 (0.39)
SCHEMBL18327484 0.76 ALDH1A1 (0.39)
SCHEMBL16661417 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459543-B1 BENZO[E][1,3]OXAZIN-4-ONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS KARUS THERAPEUTICS LTD (GB) 2017-08-30 EP disclosed
US-20160368908-A1 BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS PRINCIPIA BIOPHARMA, INC. 2016-12-22 US disclosed
US-20090163493-A9 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor SERENEX, INC. 2009-06-25 US disclosed
US-20080096887-A1 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor SERENEX, INC. 2008-04-24 US disclosed